Screening of Brain Metastasis with Limited Magnetic Resonance Imaging (MRI):Clinical Implications of Using Limited Brain MRI During Initial Staging for Non-small Cell Lung Cancer Patients.
10.3346/jkms.2005.20.1.121
- Author:
Sun Young KIM
1
;
Jae Sung KIM
;
Hee Sun PARK
;
Moon June CHO
;
Ju Ock KIM
;
Jin Whan KIM
;
Chang Jun SONG
;
Seung Pyung LIM
;
Sung Soo JUNG
Author Information
1. Department of Internal Medicine, College of Medicine, Cancer Research Institute, Chungnam National University, Daejon, Korea. jss24@cnuh.co.kr
- Publication Type:Original Article
- Keywords:
Carcinoma, Non-Small-Cell Lung;
Neoplasm Staging;
Neoplasm Metastasis;
Magnetic Reso-nance Imaging;
Diagnosis;
Radiography
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Brain Neoplasms/*diagnosis/pathology/*secondary;
Carcinoma, Non-Small-Cell Lung/*diagnosis/*pathology;
Female;
Humans;
Lung Neoplasms/*diagnosis/pathology;
Magnetic Resonance Imaging/*economics/methods;
Male;
Middle Aged;
Neoplasm Metastasis;
Prognosis;
Time Factors
- From:Journal of Korean Medical Science
2005;20(1):121-126
- CountryRepublic of Korea
- Language:English
-
Abstract:
The purpose of this prospective study was to determine whether using magnetic resonance imaging (MRI) for early screening for brain metastases (BM) can improve quality of life, survival in patients with non-small cell lung cancer (NSCLC). The study group comprised 183 patients newly diagnosed with NSCLC. All patients underwent limited brain MRI and routine workups. The control group comprised 131 patients with NSCLC who underwent limited brain MRI only if they had neurologic symptoms. The incidence of BM was 20.8% (38/183) in the study group and 4.6% (6/131) in the control group. The rate of upstaging based on the MRI data was 13.5% (15/111) overall and 15.9% (11/69) in patients that had been considered initially to be resectable surgically. There was no significant difference in survival outcome between the groups. Patients who had BM alone had a greater overall survival time (49 weeks) than those who had multiple systemic metastases (27 weeks; p=0.0307). In conclusions, limited brain MRI appears to be a useful, costeffective method to screen for BM at the time of initial staging. And it may facilitate timely treatment of patients with NSCLC and improve their survival and quality of life.
